Dr. Fumei Shang: Attending physician at Nanyang City Central Hospital, China
Dr. Fumei Shang is an accomplished attending physician and oncology researcher from China, specializing in tumor biology and the interplay between microbial flora and cancer. Holding a PhD in Oncology, she combines clinical expertise with advanced scientific research, particularly focusing on how intestinal microbiota affects tumor progression and immunotherapy outcomes. Known for her dedication, strong sense of responsibility, and excellent communication skills, Dr. Shang has contributed significantly to both clinical practice and academic research.
Online Profiles
Dr. Fumei Shang is currently affiliated with the Cancer Center in San Diego, United States, and has a strong international academic presence. Her Scopus Author ID is 56808889300, with a record of 13 published documents, 314 citations across 311 documents, and an h-index of 7, reflecting the growing impact and relevance of her research. She is encouraged to link her Scopus profile to ORCID for broader academic visibility and integration. Dr. Shang actively reviews for peer-reviewed journals and is recognized in the global oncology and microbiome research communities.
Education
Dr. Shang completed her doctoral studies in Oncology, where she extensively studied tumor microenvironment dynamics and the role of microbial communities in cancer biology. Her education provided a solid foundation in clinical oncology, molecular biology, and bioinformatics, equipping her with skills to integrate multi-omics approaches and machine learning techniques in cancer research.
Research Focus
Her primary research explores the complex interactions between tumors and microbial flora, with an emphasis on intestinal bacteria’s influence on immune response and immunotherapy efficacy in cancers such as non-small cell lung cancer and colorectal cancer. She also investigates microbial biomarkers predictive of therapeutic outcomes and the potential of microbiota transplantation as an adjuvant cancer treatment.
Experience
Dr. Shang has an extensive track record as principal investigator and collaborator on numerous research projects funded by national and provincial grants, including six projects where she served as the lead applicant. She has published 12 peer-reviewed articles, with several focusing on the tumor microbiome and immunotherapy. She is also an active peer reviewer for several respected scientific journals, contributing her expertise to advancing oncology research globally.
Research Timeline & Activities
Since 2015, Dr. Shang has led and contributed to a variety of research initiatives, ranging from undergraduate student training projects to major provincial scientific research programs. Her recent projects include studies on the modulation of immunotherapy efficacy through intestinal flora and the development of predictive models for treatment response in gene-negative NSCLC patients. These activities underscore her continuous commitment to bridging clinical oncology and microbiome science.
Awards & Honors
Dr. Shang’s research has earned significant recognition, particularly her highly cited review on Fusobacterium nucleatum and colorectal cancer, which has been acknowledged by leading journals such as Nature Reviews Gastroenterology & Hepatology. She is an active member of multiple professional oncology associations in China, including committees dedicated to tumor diagnosis, cancer prevention, and lung cancer research, reflecting her leadership and influence in the field.
Top Noted Publication
Her landmark paper, “Fusobacterium nucleatum and colorectal cancer: A review,” published in World Journal of Gastrointestinal Oncology (2018), has been cited over 100 times and is considered a seminal work in the understanding of microbial contributions to colorectal carcinogenesis. This publication has influenced further research on the tumor microbiome and been highly praised in reviews by top-tier journals, highlighting Dr. Shang’s role as a thought leader in this area.
1. Shang, F., Huang, M., Ji, Y., Zhang, S., et al.
Harnessing Machine Learning and Multiomics to Construct a Tumor-Specific T Cell Signature for Prognostic Assessment and Precision Medicine in Lung Adenocarcinoma
Annals of Surgical Oncology, Sep 2025
This study integrated scRNA-seq, bulk transcriptomic data, and spatial transcriptomics to construct a T cell-related gene prognostic indicator (TRGPI) for lung adenocarcinoma (LUAD). The model demonstrated strong predictive value for immunotherapy response and survival, with TPI1 identified as a key TRG. This work presents a significant advancement in precision oncology and immunotherapy stratification.
**2. Jin, M., Fan, Q., Shang, F., et al.
Fusobacteria Alterations Are Associated With Colorectal Cancer Liver Metastasis and a Poor Prognosis
Oncology Letters, Mar 2024
This study used 16S rRNA sequencing across multiple cohorts to show that Fusobacteria enrichment is consistently associated with colorectal cancer liver metastasis (LM) and poor survival outcomes. It identified Fusobacteria as a potential microbial biomarker for metastasis and prognosis, contributing to microbiota-based diagnostics in CRC.
**3. Cao, Y., Shang, F., Jin, M., et al.
Changes in Bacteroides and the Microbiota in Patients With Obstructed Colorectal Cancer: A Retrospective Cohort Study
BJS Open, Nov 2023
This retrospective analysis revealed that CRC patients with intestinal obstruction exhibit significantly altered microbial diversity, particularly an increase in Bacteroides. Obstruction was associated with worse clinical outcomes and shifts in tumor microecology, indicating a role of the microbiota in modulating CRC progression.
**4. Shang, F., Cao, Y., Wan, L., et al.
Comparison of Helicobacter pylori Positive and Negative Gastric Cancer via Multi-Omics Analysis
mBio®, Oct 2023
This multi-omics investigation uncovered significant genetic, microbial, and metabolic differences in gastric cancer patients with and without H. pylori infection. It identified novel biomarkers (e.g., GCG, APOA1, IGFBP1) and 295 differential metabolites, providing mechanistic insight into H. pylori-associated carcinogenesis.
**5. Jiang, Z., Yan, L., Deng, S., Shang, F., et al.
Development and Interpretation of a Clinicopathological-Based Model for the Identification of Microsatellite Instability in Colorectal Cancer
Disease Markers, Feb 2023
This study utilized machine learning (RF, SVM, XGBoost) to build predictive models for identifying dMMR/pMMR status using clinical features. The random forest model outperformed traditional logistic regression, offering a fast, cost-effective alternative to molecular testing in CRC treatment planning.
Strength for the Innovative Researcher Award:
1. Pioneering Research at the Tumor-Microbiome Interface
Dr. Shang has made groundbreaking contributions to the understanding of how microbial flora influences cancer progression and treatment, especially in colorectal and lung cancers. Her highly cited review on Fusobacterium nucleatum and colorectal cancer has shaped current perspectives in the field and established microbial biomarkers as viable clinical tools. Her research continues to bridge gaps between oncology and microbiome science, a frontier area in precision medicine.
2. Integration of Multi-Omics and Machine Learning in Oncology
In her recent work published in Annals of Surgical Oncology (2025), Dr. Shang demonstrated exceptional innovation by integrating single-cell RNA sequencing, spatial transcriptomics, and bulk RNA data to construct a T cell prognostic signature (TRGPI) for lung adenocarcinoma. This project reflects her strength in data-driven precision oncology, combining bioinformatics, immunology, and AI for clinically translatable outcomes.
3. International Recognition and Collaborative Impact
With over 314 citations and an h-index of 7, Dr. Shang’s research has garnered international attention. Her transition from China’s Nanyang City Central Hospital to the Cancer Center in San Diego has facilitated impactful cross-border collaborations, enhancing the global relevance of her work. Her dual affiliation exemplifies her role as a global academic connector and research leader.
4. Clinical Translation and Diagnostic Innovation
Dr. Shang has consistently aligned her research with clinical applicability. For example, her clinicopathological model for MSI prediction in CRC (published in Disease Markers, 2023) offers a low-cost, high-accuracy alternative to molecular testing, demonstrating her ability to translate computational models into real-world diagnostics that benefit patients in resource-limited settings.
5. Leadership in Funded Research and Mentorship
Dr. Shang has led six nationally and provincially funded research projects, underlining her ability to design, secure, and lead innovative investigations. Her mentorship of undergraduate research projects and collaboration in multidisciplinary studies reflect her dedication to capacity-building and scientific leadership, nurturing the next generation of oncology researchers.